ACTRN12605000601639已完成2 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. A phase II dose finding and proof of principle trial.ODIXa-DVT
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Patients with acute symptomatic proximal deep vein thrombosis (objectively confirmed by complete compression ultrasound).
排除标准
- •Related to medical historyTIA or ischemic stroke within the last 6 months prior to study entry.History of heparin-induced thrombocytopenia, allergy to heparins.Intracerebral or intraocular bleeding within the last 6 months prior to study entry.History of gastrointestinal bleeding within the last 6 months prior to the study.History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug.Related to current symptoms or findingsFemale with childbearing potential using no adequate contraception method.Pregnant and breastfeeding women.Symptomatic pulmonary embolism.Surgery either major or minor within the last 10 days.Neurosurgery within the last 4 weeks.Heart insufficiency NYHA III-IV.Bacterial endocarditis.Known congenital or acquired hemorrhagic diathesis including patients with acquired or congenital thrombopathy.Thrombocytopenia.Macroscopic hematuria.Uncontrolled severe hypertension.Impaired liver function (transaminases > 2 x ULN).Impaired renal function.Patients with known brain metastases.Patients receiving cytotoxic chemotherapy.Life-expectancy < 6 months.Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding or any other increased risk for bleeding (eg diabetic retinopathy).Body weight < 45 kg.Drug-or alcohol abuse.Related to current treatment Therapy with oral anticoagulants, heparins or factor Xa inhibitors other than study medication are not allowed.Therapy with platelet aggregation inhibitors must be stopped prior to randomization. Patients where continued treatment with platelet aggregation inhibitors is clinically indicated will be excluded. The therapy with acetylicsalicylic acid at daily doses up to 500 mg/d is allowed during the study and prior to randomization. Any treatment prior to randomization with heparins (exception: unfractionated heparin treatment within 36 hours, 2 therapeutic doses of a LMWH 24 hours apart or 3 therapeutic doses of a LMWH 12 hours apart. Prophylactic doses of UFH or LMWH are allowed).Fibrinolytic agents are not allowed during the study.All other drugs influencing coagulation (exception: NSAIDs with half-life < 17 hours) are not allowed during the study.Systemic and local topical treatment with azole compounds and other strong CYP3A4 inhibitors are not allowed within 4 days prior to randomization and during the study.
研究者
相似试验
进行中（未招募）
1 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein ThrombosisODIXa-DVTA prospective, randomized, multinational, multicenter, partially blinded, parallel-group, open-label active comparator controlled phase II Dose Finding and Proof of Principle Trial. - ODIXa-DVTEUCTR2004-001083-43-GBBayer HealthCare AG
进行中（未招募）
1 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein ThrombosisODIXa-DVTA prospective, randomized, multinational, multicenter, partially blinded, parallel-group, open-label active comparator controlled phase II Dose Finding and Proof of Principle Trial. - ODIXa-DVTEUCTR2004-001083-43-HUBayer HealthCare AG
进行中（未招募）
1 期
Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. - Einstein-DVT dose-finding studyEUCTR2004-002171-16-DKBayer HealthCare AG
进行中（未招募）
不适用
Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. - Einstein-DVT dose-finding studyEUCTR2004-002171-16-SEBayer HealthCare AG520
进行中（未招募）
不适用
Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. - Einstein-DVT dose-finding studyAcute symptomatic deep vein thrombosisMedDRA version: 7.0Classification code 10051055EUCTR2004-002171-16-CZBayer HealthCare AG520